BioSpace News Archive

–IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021 – - Collaboration with Ultragenyx creates opportunities to develop additional gene therapies for Duchene muscular dystrophy- – Enhanced cash position resulting from Ultragenyx collaboration and fund-raising activity expected to provide financial runway into the second half of 2021 – – Conference call and webcast scheduled for 8:30 AM ET –

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the three and nine months ended September 30, 2020, and provided operational updates.

FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer PDUFA dates for tirbanibulin ointment and Oral Paclitaxel set for December 30, 2020 and February 28, 2021, respectively Four abstracts featuring Oral Paclitaxel accepted for presentation at San Antonio Breast Cancer Virtual Symposium Product sales in Q3 2020 were $24.8 million, up 29% y/y -- raising full year 2020 guidance to low 20% growth

Avanos Medical, Inc. (NYSE: AVNS) today announced that it would present at the following two virtual investor conferences in November: Conference : Stifel 2020 Virtual Healthcare Conference Pres

Madrigal Pharmaceuticals, Inc. announced that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with presumed NASH who are diagnosed using non-invasive assessments.

Pappas Capital, a leading venture capital firm focused on advancing life sciences, announced that its portfolio company, VelosBio Inc., has entered into a definitive agreement to be acquired by a subsidiary of Merck for $2.75 billion in cash, subject to customary adjustments.

Ra Medical Systems, Inc. announces that it will report third quarter 2020 financial results and provide a business update after market close on Thursday, November 12, 2020.

Completed Rolling NDA Submissions for Both BCV Tablet and SuspensionFormulations as Medical Countermeasure for Smallpox

VYNE Therapeutics Inc. announced financial results for the third quarter ended September 30, 2020 and provided a corporate update.

Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant i mprovements in multiple measures associated with age-related cognitive decline and neurodegenerative diseases Company revamping its organization to focus on critical IW-6463 CNS program priorities; expects 2021 average cash use reduction of approximately 50% from Q3 2020 levels